Adenosine injection is indicated for supraventricular tachycardia in cardiac patients.
Arthur Przybyl, Akorn’s president and CEO, said: “We are pleased to announce the abbreviated new drug application (ANDA) approval for Adenosine. This product is manufactured at our Decatur, Illinois manufacturing facility and represents another important addition to our injectable product line. We expect to launch Adenosine in 2009.”